Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice

被引:61
作者
Acton, DS
Velthuyzen, D
Lips, CJM
Höppener, JWM
机构
[1] Univ Utrecht, Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands
关键词
medullary thyroid carcinoma; multiple endocrine neoplasia type 2B; human RET transgenic mice;
D O I
10.1038/sj.onc.1203648
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple endocrine neoplasia type 2B (MEN 2B) is a familial cancer syndrome, in which the cardinal feature is medullary thyroid carcinoma (MTC), a malignant tumor arising from the calcitonin producing thyroid C-cells, MEN 2B is associated with a germline point mutation in the RET proto-oncogene, leading to a Met-->Thr substitution at codon 918 in the kinase domain, which alters the substrate specificity of the protein. we used the human calcitonin gene (CALC-1) promoter to generate transgenic mice expressing either the human RET oncogene with the MEN2B-specific 918 Met-->Thr mutation (CALC-MEN2B-RET) or the human nonmutated RET proto-oncogene (CALC-WT-AET) in the C-cells, At 20-22 months of age three out of eight CALC-MEN2B-RET transgenic founders presented with macroscopic bilateral MTC, In two founders nodular C-cell hyperplasia (CCH) was observed. Thyroid abnormalities were never observed in CALC-WT-RET transgenic mice or control non-transgenic mice analysed at this age. In some mice from established CALC-MEN2B-RET transgenic lines nodular CCH was observed from 8 months on whereas MTC was detected in 13% of mice from one CALC-MEN2B-RET line, from the age of 11 months on. These results show for the first time that the MEN2B mutation in the RET oncogene predisposes mice for MTC.
引用
收藏
页码:3121 / 3125
页数:5
相关论文
共 24 条
  • [1] ASAI N, 1995, MOL CELL BIOL, V15, P1613
  • [2] SINGLE MISSENSE MUTATION IN THE TYROSINE KINASE CATALYTIC DOMAIN OF THE RET PROTOONCOGENE IS ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B
    CARLSON, KM
    DOU, SS
    CHI, D
    SCAVARDA, N
    TOSHIMA, K
    JACKSON, CE
    WELLS, SA
    GOODFELLOW, PJ
    DONISKELLER, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) : 1579 - 1583
  • [3] CARNEY JA, 1976, ORAL SURG ORAL MED O, V41, P793
  • [4] RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer
    Coxon, AB
    Ward, JM
    Geradts, J
    Otterson, GA
    Zajac-Kaye, M
    Kaye, FJ
    [J]. ONCOGENE, 1998, 17 (12) : 1625 - 1628
  • [5] DONISKELLER H, 1993, HUM MOL GENET, V2, P1579
  • [6] POINT MUTATION WITHIN THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B AND RELATED SPORADIC TUMORS
    ENG, C
    SMITH, DP
    MULLIGAN, LM
    NAGAI, MA
    HEALEY, CS
    PONDER, MA
    GARDNER, E
    SCHEUMANN, GFW
    JACKSON, CE
    TUNNACLIFFE, A
    PONDER, BAJ
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (02) : 237 - 241
  • [7] A MUTATION IN THE RET PROTOONCOGENE ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE-2B AND SPORADIC MEDULLARY-THYROID CARCINOMA
    HOFSTRA, RMW
    LANDSVATER, RM
    CECCHERINI, I
    STULP, RP
    STELWAGEN, T
    LUO, Y
    PASINI, B
    HOPPENER, JWM
    VANAMSTEL, HKP
    ROMEO, G
    LIPS, CJM
    BUYS, CHCM
    [J]. NATURE, 1994, 367 (6461) : 375 - 376
  • [8] HORN RC, 1951, CANCER, V4, P697, DOI 10.1002/1097-0142(195107)4:4<697::AID-CNCR2820040407>3.0.CO
  • [9] 2-8
  • [10] Landsvater RM, 1996, CANCER RES, V56, P4853